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Abstract
Background: Detection of atrial fibrillation after ischemic stroke is challenging due to its paroxysmal nature. We
aimed to assess predictors of paroxysmal atrial fibrillation using non-invasive surface ECG and transthoracic
echocardiography to select candidates for atrial fibrillation screening.
Methods: Ischemic stroke patients without documented atrial fibrillation (n = 110, 67 ± 10 years, 40 female) and a
control group of age- and gender-matched patients with history of paroxysmal atrial fibrillation prior to stroke
(n = 55, 67 ± 10 years, 19 female) comprised the study sample. Using non-invasive ECG monitoring for three weeks,
short episodes of paroxysmal atrial fibrillation were detected in 24 of 110 patients (22 %). The standard 12-lead ECG
with sinus rhythm at stroke onset was digitally processed and analyzed. Transthoracic echocardiography data were
reviewed for these patients.
Results: Atrial fibrillation history was independently associated with P terminal force in lead V 1 > 40 mm*ms (OR 4.04
95 % CI 1.34–12.14, p = 0.013) and left atrial volume index (OR 1.08 95 % CI 1.03–1.13, p = 0.002; for LAVI > 40 mL/m2
OR 6.40 95 % CL 1.47–27.91, p = 0.013). Among patients without atrial fibrillation history, no ECG characteristics were
predictive of atrial fibrillation detected after stroke. Left atrial volume index remained an independent predictor of atrial
fibrillation detected after stroke (OR 1.09 95 % CI 1.02–1.16, p = 0.017). A cutoff of <40 mL/m2 had an 84 % negative
predictive value for ruling out atrial fibrillation on ambulatory monitoring with a sensitivity of 50 % and a specificity of
86 %.
Conclusion: In a post hoc analysis, left atrial dilatation assessed by left atrial volume index independently predicted
atrial fibrillation after stroke in patients without prior atrial fibrillation history, while the other clinical or ECG markers
were not predictive of atrial fibrillation detected early after ischemic stroke.
Trial registration: This study is a post hoc analysis from the prospective case-control study registered in December
2011, ClinicalTrials.gov ID: NCT01325545.
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Background
The high prevalence of atrial fibrillation (AF) in ischemic
stroke patients is well-documented [1, 2]. Detecting AF
after ischemic stroke is important, as anticoagulation
therapy, as opposed to aspirin, is hence used to prevent
recurrent thromboembolic events. However, paroxysmal
AF is often underdiagnosed. Routine diagnostic screen-
ing techniques, such as 24-h Holter ECG monitoring,
have modest sensitivity for AF detection [3, 4]. Pro-
longed electrocardiographic (ECG) monitoring increases
the detection rate of AF after a stroke [5]. However, the
highest detection rate of AF after cryptogenic stroke was
reported in stroke patients with implantable cardiac
monitors (ICM) [6]. While ICM-based strategy for AF
detection is clearly superior to other ECG monitoring
techniques, its cost effectiveness is largely affected by
proper patient selection, which highlights the need for
developing AF risk prediction tools.
Atrial remodeling in patients with known AF can be
demonstrated using available non-invasive techniques,
such as surface ECG and transthoracic echocardiography
(TTE). It is not fully clear whether the same ECG and
TTE measures are associated with newly-detected AF
after ischemic stroke and may be used to select candi-
dates for more costly and time consuming AF screening.
Frequent supraventricular ectopic activity, including
frequent supraventricular premature complexes and sup-
raventricular runs detected by 24-h Holter ECG moni-
toring, are predictive of AF [7, 8]. A case-control study
using ambulatory ECG monitoring for three weeks after
a stroke showed that short episodes of asymptomatic AF
are common in both patients with cryptogenic stroke
and patients with stroke of known cause [9]. Identifying
clinical markers predictive of AF after stroke would
facilitate AF screening in patients at high risk for devel-
oping arrhythmia, and help optimize the use of health
care resources.
We aimed to investigate clinical, ECG and TTE char-
acteristics associated with paroxysmal AF in ischemic
stroke patients, and to assess whether the same clinical,
ECG and TTE parameters are predictive of paroxysmal




The study cohort was recruited from the cohort of ische-
mic stroke patients treated at Mayo Clinic (Rochester,
MN, USA). Patients without history of AF or atrial flutter
prior to or at the index stroke event were compared with
patients with documented paroxysmal AF by admission
with stroke.
Study group of patients without AF history comprised
of 110 patients with ischemic stroke of either cryptogenic
(n = 55) or known cause (n = 55) who were previously in-
cluded in the recently published analysis [9] and who had
a surface ECG during sinus rhythm obtained at stroke on-
set (mean age 67 ± 10 years, 40 female). Using ambulatory
ECG monitoring for three weeks (Mobile Cardiac Out-
patient Telemetry system - CardioNet, Conshohocken,
PA, USA), short AF episodes of median 6 s duration (IQR
6–9) were detected in 24 patients (22 %). All arrhythmic
episodes were manually reviewed by a board certified
electrophysiologist. The 24 patients with newly detected
short AF episodes after stroke (ShortAF Group) were
compared to the 86 stroke patients without detected AF
(NoAF Group).
Control group was randomly selected from age- and
gender-matched patients treated at Mayo Clinic with
ischemic stroke with history of paroxysmal AF prior to
stroke and sinus rhythm on standard 12-lead ECG at ad-
mission (PxAF Group, n = 55, 67 ± 10 years, 19 female).
The Mayo Clinic Institutional Review Board approved
the research protocol.
Baseline assessment
Baseline clinical assessment included demographics,
body mass index (BMI), comorbid conditions such as
cardiac failure, hypertension, ischemic heart diseases,
stroke or transient ischemic attack in the past, diabetes
and cardiovascular risk profile measured by CHADS2
and CHA2DS2-VASc scales [10].
ECG analysis
Standard clinical 12-lead ECG recordings with sinus
rhythm were obtained at enrollment in all study sub-
jects. Digital signals were extracted and stored in a for-
mat readable by MegaCare ECG management system
(Siemens-Elema, Stockholm, Sweden. Discontinued).
Standard clinical measurements, i.e., P-wave duration,
QRS duration, corrected QT interval (using Bazett’s for-
mula), PQ interval and P-wave terminal force in Lead
V1 were obtained from the MegaCare system using the
University of Glasgow 12-lead ECG analysis algorithm
[11]. P-wave terminal force in Lead V1 was defined as
duration, in milliseconds, of the terminal (negative) part
of the P wave multiplied by its depth in millimeters [12].
P-wave morphology assessment was performed using
custom-made software running on MATLAB R2013b
(The MathWorks, Inc., Natick, MA, USA) for Linux.
The 12-lead ECG was mathematically transformed into
orthogonal leads using the pseudo-inverse of the Dower
transformation matrix [13]. The orthogonal leads were
denoted X (right-left), Y (up-down), and Z (front-back).
In addition to conventional P-wave indices, we ana-
lyzed gross morphology of P-waves using an automatic
algorithm [14] that classified orthogonal P waves into
types as having positive polarity in leads X and Y and
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negative, biphasic (-/+) or positive polarity in lead Z. Bi-
phasic (+/-) P-waves in inferior lead Y have been defined
as an advanced interatrial block with retrograde left
atrial activation (IAB).
Echocardiography
Results of clinically indicated TTE were retrieved from
patient medical records. TTE examinations were per-
formed at median 1 day (interquartile range 25–75 %
(IQR) -10.9 to 2.9 months) from the stroke event. We
assessed the left atrial volume index (LAVI, ml/m2), ejec-
tion fraction (EF), estimated right atrial pressure using
inferior vena cava size and respiratory variation (mm
Hg), right ventricular pressure (mm Hg), left ventricular
end-systolic and end-diastolic internal dimensions (mm).
Statistical methods
Clinical characteristics, ECG and TTE parameters were
compared between patients in the NoAF Group and pa-
tients in the ShortAF Group using chi-square or Fisher’s
exact test for categorical variables and Student’s t-test for
continuous variables with an approximate normal distribu-
tion or alternatively non-parametric tests, as appropriate.
To identify predictors of paroxysmal AF on prolonged
ambulatory ECG monitoring, significantly associated co-
variates were further evaluated in univariate logistic re-
gression models with estimation of odds ratios and
likelihood-ratio tests. Factors significantly associated
with occurrence of short AF episodes on ECG monitor-
ing in the univariate models were subsequently included
in a stepwise multivariate regression analysis with back-
wards elimination. Predictive accuracy of covariates de-
termined in multivariate logistic regression models was
evaluated using receiver operating characteristic (ROC)
curve analysis with calculation of positive predictive
value, negative predictive value, sensitivity and specificity
of the determined parameters.
The group of patients without history of AF prior to
or at the index stroke event was compared to patients in
the PxAF Group. Univariate logistic regression analysis
was performed to identify covariates significantly associ-
ated with AF history that were further included in a
stepwise multivariate regression analysis with backwards
elimination. Threshold values for F-to-enter and F-to-
remove were 0.05 and 0.1, respectively.
All analyses were performed using SPSS Statistics 20
(SPSS Inc., Chicago, Illinois, USA). P-values of <0.05
were considered significant.
Results
Clinical characteristics associated with history of
paroxysmal AF in ischemic stroke patients
PxAF patients had a higher proportion of vascular
diseases, cardiac failure and higher cardiovascular risk
profile measured by CHADS2 and CHA2DS2-VASc
scales than patients without AF at baseline (Table 1).
Analysis of ECG data showed that P-wave duration,
QRS duration, corrected QT interval were longer, and P-
wave terminal force in lead V1 was greater in PxAF
patients than in patients without AF at stroke. The dis-
tribution of different P-wave morphologies was similar
in both groups. P-wave morphology with positive P-
waves in leads X, Y and biphasic P-wave in lead Z was
the most prevalent type in our study cohort.
TTE examination revealed that patients with AF history
had lower EF, higher right atrium systolic pressure, larger
left ventricular end-systolic and end-diastolic internal di-
mensions and greater LAVI than patients without AF.
However, in multivariate logistic regression analysis,
only vascular diseases (odds ratio (OR) 4.10 95 % CI 1.32–
12.78, p = 0.015), P-wave terminal force in lead V1 greater
40 mm*ms (OR 4.04 95 % CI 1.34–12.14, p = 0.013) and
LAVI (OR 1.08 95 % CI 1.03–1.13, p = 0.002) remained
significantly associated with AF prior to stroke.
Predictors of short AF episodes detected after ischemic
stroke in patients without AF history
Clinical, ECG and TTE data are summarized in the Table 2.
Patients with AF detected on ECG monitoring were
older than patients without detected AF, with no differ-
ences in sex, BMI, cardiovascular comorbidities or
cardiovascular risk profile measured by CHADS2 and
CHA2DS2-VASc scales. These patients had greater LAVI
than patients without AF, and there were no differences
in other ECG (including P-wave morphology) and TTE
characteristics.
In univariate regression analysis, detection of short AF
episodes after stroke was associated only with age and
LAVI. However, LAVI remained the only independent
predictor of AF in multivariate regression analysis
(Table 3).
The area under the ROC curve values for LAVI as an
indicator of the short AF episodes detected by ambula-
tory ECG monitoring was 0.698, p = 0.041 (Fig. 1). A
cutoff of <40 mL/m2 had a positive predictive value of
55 % and an 84 % negative predictive value for ruling
out AF on ambulatory monitoring, with sensitivity 50 %
and specificity 86 %.
Discussion
Detecting AF after ischemic stroke is challenging due to
its paroxysmal nature. Studies with implantable devices
have shown that most AF episodes are asymptomatic
[15, 16], and thus AF often remains undetected. Routine
ECG monitoring strategies have moderate sensitivity in
AF detection, and there is therefore a need to find a sim-
ple non-invasive tool to identify stroke survivors who
would benefit more from continuous screening for AF.
Baturova et al. BMC Cardiovascular Disorders  (2016) 16:209 Page 3 of 8
Our main finding is that left atrial dilatation measured
by LAVI is the strongest independent predictor of subse-
quent detection of short AF episodes during prolonged
ECG monitoring in patients without AF at stroke onset.
ECG data, including P-wave morphology, and underlying
comorbidities have limited value for predicting paroxys-
mal AF after ischemic stroke. In patients with known
paroxysmal AF, however, a negative terminal deflection
in V1 was a strong indicator of arrhythmia.
The novelty of our finding is that the presence of elec-
trocardiographic abnormalities in patients with known
AF, but not in those without history of AF, suggests that
initially there is development of subtle structural
changes seen by TTE (increased LAVI), and electrocar-
diographic abnormalities are only seen later.
Short episodes of paroxysmal AF
In patients without AF history at stroke onset, we found
very short episodes of paroxysmal AF during 3 weeks of
ECG monitoring. It is still under discussion whether
ultra-short AF episodes of less than 30 s have the same
risk of thromboembolic complications as manifested AF
[17]. However, it has been shown that supraventricular
runs and high supraventricular ectopic activity are
predictive of AF occurrence [7, 8]. In ischemic stroke
patients, premature atrial complexes that occur more
frequently than 4 per hour and atrial runs that exceed 5
complexes were associated with occurrence of paroxys-
mal AF [18]. Studies with loop recorders implanted for
AF screening after ischemic stroke reported detection of
AF lasting 2 min or longer on average 48–68 days after
implantation [19, 20]. While short episodes of paroxys-
mal AF were common for our ischemic stroke cohort
who underwent ambulatory ECG monitoring for 3 weeks,
the monitoring time was perhaps not long enough to re-
veal full incidence of underlying asymptomatic AF in
this stroke cohort. Short episodes of paroxysmal AF may
be considered as “surrogates” for prolonged AF that
Table 1 Clinical, ECG and Echocardiographic characteristics of stroke patients without AF history at stroke onset and patients with
history of AF prior to stroke
Variables Patients without AF history, n = 110 Patients with PxAF, n = 55 P value
Mean age, yearsa 67 ± 10 68 ± 10 0.686
Female, n (%) 40 (36) 19 (35) 0.864
BMIa 29 ± 5 29 ± 5 0.790
P-wave duration, msa 137 ± 16 145 ± 17 0.003
Patients with P-wave duration > 120 ms, n (%) 90 (82) 47 (85) 0.387
PR-interval, msa 172 ± 28 178 ± 35 0.189
P-wave terminal force in lead V1, mm x msa 24 ± 26 35 ± 33 0.020
QRS duration, msa 100 ± 17 107 ± 21 0.021
Corrected QTc interval, msa 430 ± 28 454 ± 34 <0.001
P-wave morphology 0.435
X(+)Y(+)Z(-), n (%) 19 (19) 8 (16)
X(+)Y(+)Z(-/+), n (%) 60 (59) 32 (64)
IAB or X(+)Y(+/-), n (%) 2 (2) 3 (6)
X(+)Y(+)Z(+), n (%) 21 (21) 7 (14)
Left atrium volume index, ml/m2 35 ± 12 45 ± 12 <0.001
EF, %a 58 ± 12 52 ± 15 0.027
Left ventricular end-systolic internal demension, mma 33 ± 9 37 ± 10 0.033
Left ventricular end-diastolic internal demension, mma 49 ± 7 52 ± 8 0.049
Right atrium pressure, mmHga 6 ± 2 8 ± 5 0.007
Right ventricular systolic pressure, mmHga 34 ± 10 36 ± 12 0.242
Diabetes, n (%) 18 (16) 12 (22) 0.399
Hypertension, n (%) 84 (76) 41 (75) 0.848
Vascular diseases, n (%) 21 (19) 20 (36) 0.021
Cardiac failure, n (%) 6 (6) 16 (29) <0.001
CHADS2 score
a 3.2 ± 0.9 3.5 ± 1.0 0.034
CHA2DS2-VASc score
a 4.9 ± 1.5 4.9 ± 1.5 0.028
a - the results are cited as mean value ± standard deviation
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should be used for identifying stroke patients who would
benefit from continuous screening for AF.
It is uncertain whether short episodes of AF indicate
the need for anticoagulation therapy. The TRENDS
study in patients with implantable devices showed that
AF burden exceeding 5.5 h during any of the preceding
30 days appeared to double the thromboembolic risk
[15]. However, in the ASSERT study in patients with im-
plantable devices it has been shown that most patients
who had stroke while being monitored did not have AF
at the time and 30 days prior to the stroke onset [16].
As reported recently, early anticoagulation therapy for
incident AF and withdrawal of anticoagulation therapy
after arrhythmia-free periods do not improve outcomes
in patients with implantable devices as compared with
conventional management [21]. Additional studies are
needed to investigate the benefit of anticoagulant
therapy in patients with short asymptomatic episodes of
paroxysmal AF.
Atrial remodeling predisposing to atrial fibrillation
Left atrial volume index
Left atrial dilatation measured as increase in LAVI may
be a marker of underlying structural changes in the
atrium leading to the development of AF in patients
without advanced cardiovascular disorders. Notably, it
has been shown that LAVI was associated with first-ever
ischemic stroke in patients without previous AF. [22]
One possible explanation for this association is that
blood stasis and thrombus formation may occur more
often in a left atrium of increased size even when AF is
not present [23]. Another possible explanation is that
these patients actually have undetected paroxysmal AF
that was not present at the time of stroke. Furthermore,
inflammation and structural changes due to underlying
comorbidity may be more important than atrial fibrilla-
tion in the development of atrial myopathy. The
CHA2DS2VASC score increases stroke risk even in the
absence of known AF [24].
Table 2 Clinical, ECG and Echocardiographic characteristics of stroke patients without AF history at stroke event
NoAF Group, n = 86 ShortAF Group, n = 24 P value
Mean age, yearsa 66 ± 10 71 ± 9 0.033
Men, n (%) 55 (64) 15 (63) 1.000
BMIa 31 ± 23 30 ± 6 0.761
P-wave duration, msa 136 ± 15 143 ± 18 0.232
Patients with P-wave duration > 120 ms, n (%) 70 (81) 20 (83) 0.451
PR-interval, msa 175 ± 29 158 ± 22 0.007
P-wave terminal force in lead V1, mm x msa 23 ± 24 28 ± 35 0.394
QRS duration, msa 100 ± 18 100 ± 15 0.962
QTc, msa 430 ± 28 430 ± 28 1.000
PW morphology 0.570
X(+)Y(+)Z(-), n (%) 16 (20) 3 (14)
X(+)Y(+)Z(-/+), n (%) 45 (56) 15 (71)
IAB or X(+)Y(+/-), n (%) 2 (3) 0 (0)
X(+)Y(+)Z(+), n (%) 18 (22) 3 (14)
Left atrium volume index, ml/m2 32 ± 10 42 ± 15 0.007
EF, % 58 ± 12 56 ± 13 0.499
Left ventricular S, mma 33 ± 9 35 ± 8 0.496
Left ventricular D, mma 49 ± 7 50 ± 6 0.679
Right atrial pressure, mmHga 6 ± 2 6 ± 2 0.498
Right ventricular systolic pressure, mmHga 33 ± 11 36 ± 7 0.490
Diabetes, n (%) 17 (20) 1 (4) 0.115
Hypertension, n (%) 66 (76) 18 (75) 1.000
Ischemic heart disease, n (%) 17 (20) 4 (17) 1.000
Cardiac failure, n (%) 4 (5) 2 (9) 0.604
CHADS2 score
a 3.2 ± 0.9 3.2 ± 0.9 0.996
CHA2DS2-VASc score
a 4.3 ± 1.5 4.5 ± 1.4 0.579
a- the results are cited as mean value ± standard deviation
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Increased LAVI reflects remodeling of left atrium due
to pressure or volume overload [25] and correlates with
the extent of left atrial fibrosis [26]. Both atrial remodel-
ing and atrial fibrosis are pathological changes associated
with the development of AF.
It has been shown that LAVI has a high diagnostic ac-
curacy for AF in hypertensive patients with historical
paroxysmal AF [27]. This was confirmed in our study
for stroke patients with known AF. We have also shown
that even in patients without history of AF, LAVI inde-
pendently predicted AF detected by ambulatory ECG
monitoring early after ischemic stroke, and can be used
in routine clinical practice as a valuable index for select-
ing patients for continuous ECG monitoring for AF de-
tection. LAVI < 40 mL/m2 has a high negative predictive
value for ruling out short AF episodes on ambulatory
ECG monitoring. This approach may decrease the num-
ber of patients undergoing ambulatory ECG monitoring
after stroke and consequently reduce costs of medical
care for this patient population. Conversely, patients
with LAVI > 40 mL/m2 are more likely to have episodes
of asymptomatic AF and should be screened for AF
more thoroughly.
In our study, LAVI was associated with history of AF in-
dependently from other TTE characteristics, and was higher
in patients with history of AF than in patients with short AF
episodes. While the difference was not significant (perhaps
due to the small number of patients with detected AF after
stroke), we observed a trend of gradual LAVI increase from
its lowest value in patients without any AF, to intermediate
volume in patients with short AF episodes, and highest
LAVI in patients with a history of AF. This trend may reflect
the underlying progression structural changes in the left
atrium in patients who develop AF.
ECG data
In order to assess ECG predictors of AF detected shortly
after ischemic stroke, we used ECG characteristics that
were reported to be associated with AF in earlier studies.
One of the most studied markers of atrial conduction
is P-wave duration. P-wave prolongation reflects atrial
Fig. 1 ROC curve for LAVI to detect short episodes of AF on ambulatory
ECG monitoring
Table 3 Covariates associated with short AF episodes on ambulatory ECG monitoring detected in patients without prior AF history
Univariate regression model Multivariate regression model (adjusted for age)
Variables OR 95 % CI P value OR 95 % CI P value
aLAVI 1.08 1.01–1.15 0.017 1.08 1.01–1.15 0.017
aLAVI > 40 ml/m2 6.40 1.47–27.91 0.013 6.40 1.47–27.91 0.013
P-wave duration 1.03 1.00–1.06 0.082
QRS duration 1.00 1.00–1.03 0.961
Corrected QT interval 1.00 1.00–1.02 0.988
PTF 1.00 1.00–1.00 0.393
EF 1.00 1.00–1.03 0.493
Left ventricle end-diatolic dimension 1.02 1.00–1.12 0.672
Left ventrical end-systolic dimension 1.03 1.00–1.10 0.488
Right atrium pressure 1.11 0.82–1.52 0.492
Age 1.05 1.00–1.11 0.037
Hypertension 0.91 0.32–2.60 0.859
Ischemic heart diseases 0.81 0.25–2.69 0.733
Cardiac failure 1.86 0.35–10.85 0.488
a- multivariate analysis was performed separately for LAVI as continuous variable and for LAVI > 40 ml/m2
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remodeling predisposing to occurrence of AF. In the
Framingham Heart Study, the prolongation of P-wave
duration predicted the development of AF during long-
term follow-up in an elderly community-based cohort
[28]. In hypertensive patients, prolonged P-wave
duration was associated with AF incidence during 25 ±
3 months [29]. In our study, the majority of patients ini-
tially had prolonged P-wave duration, but no association
was found between P-wave duration and AF on ambula-
tory ECG monitoring. These findings are in line with an
earlier report of absent association between P-wave
prolongation and incident AF among patients with ad-
vanced congestive heart failure and prolonged P-waves
at baseline in the MADIT-II study [14].
Sinus P-waves with biphasic morphology in the sagittal
plane (right precordial leads or orthogonal lead Z) quan-
tified as increase of negative terminal force in lead V1
(e.g. P terminal force in lead V1) was predominantly
found in the elderly [30] and in patients with a history
of AF [31] or structural heart disease [32]. The Athero-
sclerosis Risk in Communities study found that P ter-
minal force in lead V1 greater than 4000 μV * ms was
associated with an increased risk of AF. [33] In our
study, P terminal force in lead V1 greater than
40 mm*ms was independently associated with history of
AF, which is in line with previously reported data.
In summary, while ECG characteristics in patients with
established AF and documented arrhythmia prior to stroke
expectedly had prolonged P-waves and more prominent P
terminal force in lead V1, none of these ECG characteristics
was independently predictive of paroxysmal AF detected in
the cohort of patients without prior AF history. While pa-
tients with short AF episodes had longer P-wave duration
and greater P terminal force in lead V1, the difference did
not reach statistical significance. The apparent lack of associ-
ation between AF detection after stroke and P-wave abnor-
malities is perhaps due to the fact that most patients
included in our study had underlying cardiovascular comor-
bidities and atrial fibrosis affecting P-wave duration and
morphology. Another explanation for this is that P-wave ab-
normalities are a later finding in atrial myopathy disease
progression than LAVI enlargement, and our patients were
relatively early in their disease progression.
It is possible that we did not have enough patients
with short AF episodes detected after stroke in our
study, thus possibly undermining our ability to identify
an association with P-wave duration and morphology.
However, LAVI as a marker of structural left atrial re-
modeling was significantly associated with history of AF
and had strong predictive value for incident AF, thus
demonstrating its superiority over ECG indices. Indeed,
future studies could determine whether increased LAVI
alone may predict which patients would fulfill the indi-
cations for initiating oral anticoagulation therapy.
Study limitations
The main limitation of our study is the relatively small num-
ber of patients who had short AF episodes on ambulatory
ECG monitoring; this small patient population may affect
the interpretation of negative findings of the lack of predict-
ive value of ECG indices for incident AF. Our analysis is also
affected by limitations inherent in the study’s retrospective
design. We used cinically indicated TTE data obtained from
patients’ medical records. While most patients had TTE
done at the time of admission with ischemic stroke (median
time 1 day after stroke), we can not completely rule out the
impact of TTE timing in relation to stroke on its predictive
value with regard to new-onset AF during follow-up.
Consequently, our findings should be considered
hypothesis-generating and need to be independently
reproduced in further studies.
Conclusion
LAVI is the strongest independent predictor of paroxys-
mal AF detected after ischemic stroke. LAVI may be
considered as an early marker of asymptomatic AF in
stroke patients without history of AF and advanced
structural changes in the heart, which may help identify
patients who would benefit from intensive monitoring
for AF detection. Most stroke patients with LAVI <
40 mL/m2 are less likely to develop paroxysmal AF on
prolonged ambulatory ECG monitoring.
Abbreviations
AF: Atrial fibrillation; BMI: Body mass index; ECG: Electrocardiographic;
EF: Ejection fraction; IQR: Interquartile range 25–75 %; LAVI: Left atrial volume





This post hoc analysis is based on data collected in a study supported by an
unrestricted grant from CardioNet (Conshohocken, PA, USA), which had no
input or relationship with the present analysis. Dr. Baturova was supported by
the Swedish Institute, Dr. Platonov was supported by the Swedish Heart-Lung
Foundation and the Swedish National Health Service, Skåne University Hospital,
Lund, Sweden.
Availability of data and materials
The data supporting the results and conclusions of the survey might be
available from the corresponding author on reasonable request.
Authors’ contributions
MB made substantial contributions to data conception, design, analysis and
interpretation; she wrote the manuscript; was responsible for portions of the
content and all aspects of ensuring that any questions related to accuracy or
integrity are appropriately investigated and resolved. SS was responsible for the
data collection, analysis and interpretation; he was involved in drafting the
manuscript. JC was responsible for the data, analysis and interpretation; he was
involved in drafting the manuscript. PB made substantial contributions to
conception, design, analysis and interpretation of data; was responsible for
manuscript revision. GL was responsible for the data collection and manuscript
revision. AR made substantial contributions to conception, design, and data
acquisition, analysis and interpretation; he was involved in drafting the
manuscript. PF made substantial contributions to conception, design and data
acquisition, analysis and interpretation; he was involved in drafting the
Baturova et al. BMC Cardiovascular Disorders  (2016) 16:209 Page 7 of 8
manuscript; agreed to be accountable for all aspects of work in ensuring that
any questions related to accuracy or integrity are appropriately investigated and
resolved. PP made substantial contributions to conception, design, data
acquisition, analysis and interpretation; he was involved in drafting and revising
the manuscript; agreed to be accountable for all aspects of work in ensuring
that any questions related to accuracy or integrity are appropriately
investigated and resolved. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study is a post hoc analysis from the prospective case-control study
conducted at Mayo Clinic (ClinicalTrials.gov ID: NCT01325545). The Mayo
Clinic Institutional Review Board approved the research protocol of the case-
control study and the informed consent. All participants signed informed
consent in order to take part in the study according to research protocol.
Author details
1Department of Cardiology, Clinical Science, Lund University, Lund SE-221 85,
Sweden. 2University Clinic, St. Petersburg State University, Kadetskaya Line
13-15, St. Petersburg 199004, Russia. 3Department of Cardiology, Mayo Clinic,
200 First Street SW, Rochester, Minnesota 55902, USA. 4Department of
Neurology, Mayo Clinic, Mayo West 8B, 200 First Street SW, Mayo Clinic,
Rochester, Minnesota 55905, USA. 5Arrhythmia Clinic, Skåne University
Hospital, Lund SE-221 85, Sweden.
Received: 19 April 2016 Accepted: 25 October 2016
References
1. Henriksson KM, Farahmand B, Asberg S, Terent A, Edvardsson N. First-ever
atrial fibrillation documented after hemorrhagic or ischemic stroke: the role
of the CHADS(2) score at the time of stroke. Clin Cardiol. 2011;34(5):309–16.
2. Baturova MA, Lindgren A, Shubik YV, Olsson SB, Platonov PG.
Documentation of atrial fibrillation prior to first-ever ischemic stroke. Acta
Neurol Scand. 2014;129(6):412–9.
3. Schaer BA, Zellweger MJ, Cron TA, Kaiser CA, Osswald S. Value of routine
holter monitoring for the detection of paroxysmal atrial fibrillation in
patients with cerebral ischemic events. Stroke. 2004;35(3):e68–70.
4. Suissa L, Lachaud S, Mahagne MH. Optimal Timing and Duration of
Continuous Electrocardiographic Monitoring for Detecting Atrial Fibrillation
in Stroke Patients. J Stroke Cerebrovasc Dis. 2013;22(7):991-5.
5. Rabinstein AA. Prolonged cardiac monitoring for detection of paroxysmal
atrial fibrillation after cerebral ischemia. Stroke. 2014;45(4):1208–14.
6. Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA,
Rymer MM, Thijs V, Rogers T, Beckers F, et al. Cryptogenic stroke and
underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478–86.
7. Wallmann D, Tuller D, Wustmann K, Meier P, Isenegger J, Arnold M, Mattle
HP, Delacretaz E. Frequent atrial premature beats predict paroxysmal atrial
fibrillation in stroke patients: an opportunity for a new diagnostic strategy.
Stroke. 2007;38(8):2292–4.
8. Binici Z, Intzilakis T, Nielsen OW, Kober L, Sajadieh A. Excessive
supraventricular ectopic activity and increased risk of atrial fibrillation and
stroke. Circulation. 2010;121(17):1904–11.
9. Rabinstein AA, Fugate JE, Mandrekar J, Burns JD, Seet RC, Dupont SA, Kauffman
TJ, Asirvatham SJ, Friedman PA. Paroxysmal atrial fibrillation in cryptogenic
stroke: a case-control study. J Stroke Cerebrovasc Dis. 2013;22(8):1405–11.
10. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-
Attar N, Hindricks G, Prendergast B, et al. Guidelines for the management of
atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the
European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.
11. Macfarlane PW, Devine B, Clark E. The University of Glasgow (Uni-G) ECG
analysis program. Computers in Cardiology. 2005;32:451–4.
12. Kohsaka S, Sciacca RR, Sugioka K, Sacco RL, Homma S, Di Tullio MR.
Electrocardiographic left atrial abnormalities and risk of ischemic stroke.
Stroke. 2005;36(11):2481–3.
13. Edenbrandt L, Pahlm O. Vectorcardiogram synthesized from a 12-lead ECG:
superiority of the inverse Dower matrix. J Electrocardiol. 1988;21(4):361–7.
14. Holmqvist F, Platonov PG, McNitt S, Polonsky S, Carlson J, Zareba W, Moss
AJ. Abnormal P-wave morphology is a predictor of atrial fibrillation
development and cardiac death in MADIT II patients. Ann Noninvasive
Electrocardiol. 2010;15(1):63–72.
15. Glotzer TV, Daoud EG, Wyse DG, Singer DE, Ezekowitz MD, Hilker C, Miller C,
Qi D, Ziegler PD. The relationship between daily atrial tachyarrhythmia
burden from implantable device diagnostics and stroke risk: the TRENDS
study. Circ Arrhythm Electrophysiol. 2009;2(5):474–80.
16. Brambatti M, Connolly SJ, Gold MR, Morillo CA, Capucci A, Muto C, Lau CP, Van
Gelder IC, Hohnloser SH, Carlson M, et al. Temporal relationship between
subclinical atrial fibrillation and embolic events. Circulation. 2014;129(21):2094–9.
17. Seet RC, Friedman PA, Rabinstein AA. Prolonged rhythm monitoring for the
detection of occult paroxysmal atrial fibrillation in ischemic stroke of
unknown cause. Circulation. 2011;124(4):477–86.
18. Weber-Kruger M, Groschel K, Mende M, Seegers J, Lahno R, Haase B,
Niehaus CF, Edelmann F, Hasenfuss G, Wachter R, et al. Excessive
supraventricular ectopic activity is indicative of paroxysmal atrial fibrillation
in patients with cerebral ischemia. PLoS One. 2013;8(6). e67602.
19. Cotter PE, Martin PJ, Ring L, Warburton EA, Belham M, Pugh PJ. Incidence of
atrial fibrillation detected by implantable loop recorders in unexplained
stroke. Neurology. 2013;80(17):1546–50.
20. Ritter MA, Kochhauser S, Duning T, Reinke F, Pott C, Dechering DG, Eckardt L,
Ringelstein EB. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day
electrocardiogram versus implantable cardiac monitors. Stroke. 2013;44(5):1449–52.
21. Martin DT, Bersohn MM, Waldo AL, Wathen MS, Choucair WK, Lip GY, Ip J,
Holcomb R, Akar JG, Halperin JL. Randomized trial of atrial arrhythmia
monitoring to guide anticoagulation in patients with implanted defibrillator
and cardiac resynchronization devices. Eur Heart J. 2015;36(26):1660–8.
22. Barnes ME, Miyasaka Y, Seward JB, Gersh BJ, Rosales AG, Bailey KR, Petty GW,
Wiebers DO, Tsang TS. Left atrial volume in the prediction of first ischemic stroke in
an elderly cohort without atrial fibrillation. Mayo Clin Proc. 2004;79(8):1008–14.
23. Di Tullio MR, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of
ischemic stroke in an ethnically mixed population. Stroke. 1999;30(10):2019–24.
24. Glotzer TV, Hellkamp AS, Lee KL, Lamas GA. CHA2DS2-VASC and CHADS2 Scores
Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node
Dysfunction Independent of Atrial Fibrillation. Can J Cardiol. 2015;31(8):1004–11.
25. Abhayaratna WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ,
Tsang TS. Left atrial size: physiologic determinants and clinical applications.
J Am Coll Cardiol. 2006;47(12):2357–63.
26. Yalcin MU, Gurses KM, Kocyigit D, Canpinar H, Canpolat U, Evranos B,
Yorgun H, Sahiner ML, Kaya EB, Hazirolan T, et al. The Association of Serum
Galectin-3 Levels with Atrial Electrical and Structural Remodeling. J
Cardiovasc Electrophysiol. 2015;26(6):635-40.
27. Toh N, Kanzaki H, Nakatani S, Ohara T, Kim J, Kusano KF, Hashimura K, Ohe
T, Ito H, Kitakaze M. Left atrial volume combined with atrial pump function
identifies hypertensive patients with a history of paroxysmal atrial
fibrillation. Hypertension. 2010;55(5):1150–6.
28. Magnani JW, Johnson VM, Sullivan LM, Gorodeski EZ, Schnabel RB, Lubitz
SA, Levy D, Ellinor PT, Benjamin EJ. P wave duration and risk of longitudinal
atrial fibrillation in persons >/= 60 years old (from the Framingham Heart
Study). Am J Cardiol. 2011;107(6):917–921.e911.
29. Ciaroni S, Cuenoud L, Bloch A. Clinical study to investigate the predictive
parameters for the onset of atrial fibrillation in patients with essential
hypertension. Am Heart J. 2000;139(5):814–9.
30. Havmoller R, Carlson J, Holmqvist F, Herreros A, Meurling CJ, Olsson B,
Platonov P. Age-related changes in P wave morphology in healthy subjects.
BMC Cardiovasc Disord. 2007;7:22.
31. Platonov PG, Carlson J, Ingemansson MP, Roijer A, Hansson A, Chireikin LV,
Olsson SB. Detection of inter-atrial conduction defects with unfiltered
signal-averaged P-wave ECG in patients with lone atrial fibrillation.
Europace. 2000;2(1):32–41.
32. Holmqvist F, Platonov PG, Carlson J, Havmoller R, Waktare JE, McKenna WJ, Olsson
SB, Meurling CJ. Variable interatrial conduction illustrated in a hypertrophic
cardiomyopathy population. Ann Noninvasive Electrocardiol. 2007;12(3):227–36.
33. Magnani JW, Zhu L, Lopez F, Pencina MJ, Agarwal SK, Soliman EZ, Benjamin
EJ, Alonso A. P-wave indices and atrial fibrillation: cross-cohort assessments
from the Framingham Heart Study (FHS) and Atherosclerosis Risk in
Communities (ARIC) study. Am Heart J. 2015;169(1):53–61.e51.
Baturova et al. BMC Cardiovascular Disorders  (2016) 16:209 Page 8 of 8
